Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

MBRX has been the topic of several other research reports. Maxim Group lowered their price objective on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 26th. Roth Mkm restated a “buy” rating and set a $40.00 target price on shares of Moleculin Biotech in a research note on Friday, April 12th.

Moleculin Biotech Stock Down 7.5 %

Shares of NASDAQ:MBRX opened at $4.30 on Friday. The firm’s 50 day moving average price is $6.93 and its 200-day moving average price is $8.10. Moleculin Biotech has a twelve month low of $4.28 and a twelve month high of $15.75. The stock has a market capitalization of $9.59 million, a PE ratio of -0.32 and a beta of 1.96.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Armistice Capital LLC acquired a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned approximately 9.60% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.